| __timestamp | Halozyme Therapeutics, Inc. | PTC Therapeutics, Inc. |
|---|---|---|
| Wednesday, January 1, 2014 | 35942000 | 44820000 |
| Thursday, January 1, 2015 | 40028000 | 82080000 |
| Friday, January 1, 2016 | 45853000 | 97130000 |
| Sunday, January 1, 2017 | 53816000 | 121271000 |
| Monday, January 1, 2018 | 60804000 | 153548000 |
| Tuesday, January 1, 2019 | 77252000 | 202541000 |
| Wednesday, January 1, 2020 | 45736000 | 245164000 |
| Friday, January 1, 2021 | 50323000 | 285773000 |
| Saturday, January 1, 2022 | 143526000 | 325998000 |
| Sunday, January 1, 2023 | 149182000 | 332540000 |
| Monday, January 1, 2024 | 154335000 |
Cracking the code
In the competitive world of biotechnology, managing operational costs is crucial. This analysis compares the Selling, General, and Administrative (SG&A) expenses of Halozyme Therapeutics, Inc. and PTC Therapeutics, Inc. from 2014 to 2023. Over this period, PTC Therapeutics consistently outspent Halozyme, with its SG&A expenses peaking at over 330% higher than Halozyme's in 2023. Notably, Halozyme's expenses surged by approximately 315% from 2014 to 2023, reflecting strategic investments in growth. Meanwhile, PTC's expenses grew by around 640%, indicating aggressive expansion and market penetration efforts. The data highlights the contrasting financial strategies of these two biotech firms, offering insights into their operational priorities and market positioning. As the biotech industry evolves, understanding these financial trends is essential for investors and stakeholders aiming to navigate this dynamic sector.
Comparing SG&A Expenses: AstraZeneca PLC vs PTC Therapeutics, Inc. Trends and Insights
Sarepta Therapeutics, Inc. or Halozyme Therapeutics, Inc.: Who Manages SG&A Costs Better?
SG&A Efficiency Analysis: Comparing Ascendis Pharma A/S and PTC Therapeutics, Inc.
Operational Costs Compared: SG&A Analysis of Halozyme Therapeutics, Inc. and Grifols, S.A.
SG&A Efficiency Analysis: Comparing Halozyme Therapeutics, Inc. and Verona Pharma plc
Halozyme Therapeutics, Inc. vs CymaBay Therapeutics, Inc.: SG&A Expense Trends
Comparing SG&A Expenses: Halozyme Therapeutics, Inc. vs Lantheus Holdings, Inc. Trends and Insights
Operational Costs Compared: SG&A Analysis of Halozyme Therapeutics, Inc. and Arrowhead Pharmaceuticals, Inc.
Who Optimizes SG&A Costs Better? Halozyme Therapeutics, Inc. or MannKind Corporation
SG&A Efficiency Analysis: Comparing PTC Therapeutics, Inc. and Amicus Therapeutics, Inc.
Comparing SG&A Expenses: PTC Therapeutics, Inc. vs Taro Pharmaceutical Industries Ltd. Trends and Insights
Breaking Down SG&A Expenses: PTC Therapeutics, Inc. vs MiMedx Group, Inc.